Fair Value Calculator Fair Value Calculator
EN DE

INDSWFTLAB (INDSWFTLAB) Fair Value & Analysis

Healthcare · Market cap ₹17.9B

I INDSWFTLAB INDSWFTLAB · NSE
Price₹206.22
Fair Value₹80.96
Upside-60.7%
Quality49/100
Watch INDSWFTLAB for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹68.32 – ₹104.30

Fair value as of: Jul 3, 2026

From 15 valuation models · updated today

Share price +27.2% over the past month.

Price vs Fair Value (12 months)

₹206.22 ₹88.15 Fair Value ₹80.96 Jul 2025 Jul 2026

12‑month range ₹88.15 – ₹206.22 · fair‑value band ₹68.32 – ₹104.30 · the ₹206.22 price screens above the ₹80.96 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

INDSWFTLAB (INDSWFTLAB) currently trades at ₹206.22, while our model-based Fair Value estimate is ₹80.96 — implying the stock looks roughly 60.7% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, INDSWFTLAB generated revenue of ₹6.4B at a net margin of 6.5%. Revenue declined 66.6% year over year. It earns a return on equity of 3.2%. The balance sheet holds a net cash position of ₹4.1B. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹6.4B
Revenue growth (YoY) -66.6%
Net margin 6.5%
Return on equity 3.2%
Free cash flow −₹1.1B FY2026
P/E ratio 42.6
More key figures
Operating margin 7.3%
EPS (TTM) ₹4.84
EPS growth (YoY) -94.8%
Net cash ₹4.1B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

INDSWFTLAB reported revenue of ₹6.4B in FY2026 versus ₹10.4B in FY2022, a compound −11.4%/yr. Reported net income was ₹414M in FY2026.

Revenue −11.4%/yr
FY22 ₹10.4B
FY23 ₹12.1B
FY24 ₹12.8B
FY25 ₹5.6B
FY26 ₹6.4B
Net income
FY22 −₹21.5M
FY23 ₹476M
FY24 ₹4.2B
FY25 ₹2.5B
FY26 ₹414M

Is INDSWFTLAB fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
1276 1276 HK$57.85 HK$29.84 -48%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.01 ¥26.59 -43%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,782 ₹915.92 -49%
Zoetis Inc Z1TS34 R$26.19 R$26.01 -1%
Hansoh Pharmaceutical Group 3692 HK$29.58 HK$18.75 -37%
Divi's Laboratories Limited DIVISLAB ₹6,788 ₹2,035 -70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is INDSWFTLAB (INDSWFTLAB) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹80.96 versus a price of ₹206.22 — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INDSWFTLAB?
Our model-based fair value for INDSWFTLAB is ₹80.96 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹206.22.
What is the quality score of INDSWFTLAB?
INDSWFTLAB has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of INDSWFTLAB (INDSWFTLAB)?
INDSWFTLAB reported trailing-twelve-month revenue of about ₹6.4B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of INDSWFTLAB?
The net profit margin of INDSWFTLAB is about 6.5%, meaning it keeps roughly 6.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.